{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:36:25Z","timestamp":1780616185314,"version":"3.54.1"},"reference-count":126,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>The treatment landscape for endometrial carcinoma (EC) is undergoing a paradigm shift from traditional histopathological dualism to precision medicine grounded in the Cancer Genome Atlas (TCGA) molecular classification. The \u201cNo Specific Molecular Profile\u201d (NSMP) subgroup, the largest molecular cohort, has emerged as a particularly promising target for endocrine-based strategies. While endocrine therapy (ET) has been a mainstay for over 60 years due to its favorable safety profile, its efficacy as monotherapy remains modest. This review provides a comprehensive overview of current endocrine strategies, including traditional agents like progestins and aromatase inhibitors, and focuses on novel combination therapies designed to overcome resistance. Recent clinical trials have demonstrated that integrating molecularly targeted agents, such as CDK4\/6 and mTOR inhibitors, significantly improves clinical outcomes. Specifically, patients with TP53 wild-type status and CTNNB1 mutations exhibit exceptional responses to these combinations. Furthermore, we discuss the potential of next-generation selective estrogen receptor degraders (SERDs) and the importance of refining patient selection through robust predictive biomarkers. Driven by molecular insights, endocrine therapy is transitioning from a secondary palliative option into a definitive cornerstone of precision oncology, offering a personalized and effective treatment for patients with advanced or recurrent endometrial carcinoma.<\/jats:p>","DOI":"10.3390\/curroncol33020124","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:47:02Z","timestamp":1771508822000},"page":"124","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Endocrine Therapy for Endometrial Carcinoma: Current Evidence, Resistance Mechanisms, and Biomarker-Driven Patient Selection"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-5090","authenticated-orcid":false,"given":"Taro","family":"Yamanaka","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7569-7813","authenticated-orcid":false,"given":"Hiroshi","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-8575","authenticated-orcid":false,"given":"Tatsunori","family":"Shimoi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2332296","DOI":"10.1001\/jamanetworkopen.2023.32296","article-title":"Reproductive Factors and Endometrial Cancer Risk Among Women","volume":"6","author":"Katagiri","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1055-9965.EPI-18-0264","article-title":"Cancer Progress and Priorities: Uterine Cancer","volume":"27","author":"Felix","year":"2018","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_5","first-page":"79","article-title":"Diverging global incidence trends of early-onset cancers: Comparisons with incidence trends of later-onset cancers and mortality trends of early-onset cancers","volume":"12","author":"Terashima","year":"2025","journal-title":"Mil. Med. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"New Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"New Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab Plus Carboplatin\/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer","volume":"386","author":"Makker","year":"2022","journal-title":"New Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.ygyno.2024.07.016","article-title":"Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO\/GOG-3031\/RUBY trial","volume":"190","author":"Mirza","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/ijgc-2023-005031","article-title":"Combination of hormonal-based therapy in endometrial cancer: Ready for prime time","volume":"33","author":"Vilches","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO\u2013ESTRO\u2013ESP guidelines for the management of patients with endometrial carcinoma: Update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1016\/S1470-2045(25)00610-2","article-title":"It takes two to tango: Importance of oestrogen receptor and progesterone receptor in endometrial cancer","volume":"26","author":"Vrede","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJM196102022640503","article-title":"Progestational Agents in the Treatment of Carcinoma of the Endometrium","volume":"264","author":"Kelley","year":"1961","journal-title":"New Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network, and Levine, D.A. (2013). Integrated genomic characterization of endometrial carcinoma. Nature, 497, 67\u201373. Erratum in Nature 2013, 500, 242; https:\/\/doi.org\/10.1038\/nature12113.","DOI":"10.1038\/nature12113"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit from Adjuvant Therapy","volume":"38","author":"Powell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ijgo.15046","article-title":"Response: FIGO staging of endometrial cancer: 2023","volume":"163","author":"Berek","year":"2023","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMra1514010","article-title":"Endometrial Cancer","volume":"383","author":"Lu","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/PAS.0b013e31827f576a","article-title":"Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma","volume":"37","author":"Gilks","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_23","first-page":"424","article-title":"Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer","volume":"29","author":"Wortman","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer\u2014Combined Analysis of the PORTEC Cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/s41416-023-02203-3","article-title":"Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer","volume":"128","author":"Asami","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"100085","DOI":"10.1016\/j.modpat.2022.100085","article-title":"Grade and Estrogen Receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death","volume":"36","author":"Jamieson","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_30","unstructured":"WHO Classification of Tumours Editorial Board (2020). WHO Classification of Female Genital Tumours, International Agency for Research on Cancer. [5th ed.]. Available online: https:\/\/publications.iarc.fr\/592."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1097\/PGP.0000000000000901","article-title":"Data Set for the Reporting of Endometrial Cancer: Recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"41","author":"Selinger","year":"2022","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e080978","DOI":"10.1136\/bmj-2024-080978","article-title":"Advances in the management of endometrial cancer","volume":"388","author":"Corr","year":"2025","journal-title":"BMJ"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/ijgc-2020-001929","article-title":"PORTEC-4a: International randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer","volume":"30","author":"Heerik","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41571-025-01015-z","article-title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H\/dMMR cancers","volume":"22","author":"Ambrosini","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_35","unstructured":"National Comprehensive Cancer Network (2025, December 21). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Uterine Neoplasms. Plymouth Meeting, PA: National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/uterine-patient.pdf."},{"key":"ref_36","first-page":"51","article-title":"Estrogen Signaling in Endometrial Cancer: A Key Oncogenic Pathway with Several Open Questions","volume":"10","author":"Rodriguez","year":"2019","journal-title":"Discov. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1158\/0008-5472.CAN-19-1382","article-title":"ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells","volume":"80","author":"Rodriguez","year":"2020","journal-title":"Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/modpathol.3880051","article-title":"Theories of Endometrial Carcinogenesis: A Multidisciplinary Approach","volume":"13","author":"Sherman","year":"2000","journal-title":"Mod. Pathol"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ajog.2011.05.042","article-title":"Understanding obesity and endometrial cancer risk: Opportunities for prevention","volume":"205","author":"Schmandt","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ygyno.2025.12.001","article-title":"Associations between obesity and outcomes in pembrolizumab-treated endometrial cancer","volume":"204","author":"Patterson","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/his.15241","article-title":"The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile","volume":"85","author":"Alafraidi","year":"2024","journal-title":"Histopathology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2024.10.028","article-title":"Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer","volume":"192","author":"Vrede","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ygyno.2016.03.006","article-title":"Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer","volume":"141","author":"Backes","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/his.12096","article-title":"ER+\/PR+\/TFF3+\/IMP3\u2212 immunoprofile distinguishes endometrioid from serous and clear cell carcinomas of the endometrium: A study of 401 cases","volume":"62","author":"Yan","year":"2013","journal-title":"Histopathology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ygyno.2016.04.008","article-title":"Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study","volume":"141","author":"Atenafu","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2008.10.032","article-title":"Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer","volume":"112","author":"Jongen","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1365-2559.2009.03390.x","article-title":"WT1, p53 and hormone receptor expression in uterine serous carcinoma","volume":"55","author":"Hirschowitz","year":"2009","journal-title":"Histopathology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/IGC.0000000000000029","article-title":"Expression of Estrogen Receptor \u03b1 as a Prognostic Factor in Patients with Uterine Serous Carcinoma","volume":"24","author":"Sho","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2020.04.043","article-title":"Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification","volume":"158","author":"Kim","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PGP.0000000000001112","article-title":"Clinicopathological and Molecular Characterization of High Grade Endometrial Carcinomas of No Specific Molecular Profile (NSMP) Stratified by ER Status","volume":"45","author":"Timmermans","year":"2025","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/PAI.0000000000000232","article-title":"Clinicopathologic and Immunohistochemical Characterization of Dedifferentiated Endometrioid Adenocarcinoma","volume":"24","author":"Li","year":"2016","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/modpathol.2011.88","article-title":"Molecular markers and clinical behavior of uterine carcinosarcomas: Focus on the epithelial tumor component","volume":"24","author":"Nijman","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Kim, H., Na, K., Bae, G.E., and Kim, H.-S. (2021). Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comprehensive Immunohistochemical Analyses Using Markers for Mesonephric, Endometrioid and Serous Tumors. Diagnostics, 11.","DOI":"10.3390\/diagnostics11112042"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"154271","DOI":"10.1016\/j.prp.2022.154271","article-title":"Primary endometrial gastric (gastro-intestinal)-type carcinoma: A practical approach","volume":"241","author":"Dridi","year":"2022","journal-title":"Pathol. Res. Pr."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cjp2.82","article-title":"Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification","volume":"3","author":"Karnezis","year":"2017","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2147\/CMAR.S514680","article-title":"The Value of Integrating Hormone Receptors into Immunohistochemistry-Based Simplified Molecular Classification in Endometrial Cancer","volume":"ume 17","author":"Zhao","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Pasanen, A., Loukovaara, M., Ahvenainen, T., Vahteristo, P., and B\u00fctzow, R. (2021). Differential impact of clinicopathological risk factors within the 2 largest ProMisE molecular subgroups of endometrial carcinoma. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0253472"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41416-023-02141-0","article-title":"Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry","volume":"128","author":"Vermij","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2024.06.016","article-title":"The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup","volume":"189","author":"Aro","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Ferrari, F., Gozzini, E., Torroni, L., Rota, M., Majd, H.S., Dell\u2019aValle, C., Ferrari, F.A., and Odicino, F. (2025). Prognostic role of immunohistochemical and molecular markers in no specific molecular profile endometrial cancer: A systematic review and meta-analysis. Am. J. Obstet. Gynecol.","DOI":"10.1016\/j.ajog.2025.09.041"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.1996.14.2.357","article-title":"High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study","volume":"14","author":"Lentz","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.1999.17.6.1736","article-title":"Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group","volume":"17","author":"Thigpen","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_63","first-page":"143","article-title":"The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta-analysis","volume":"130","author":"Birkendahl","year":"2022","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2001.19.2.364","article-title":"Tamoxifen in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study","volume":"19","author":"Thigpen","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ygyno.2019.05.007","article-title":"Phase 2 study of anastrozole in recurrent estrogen (ER)\/progesterone (PR) positive endometrial cancer: The PARAGON trial\u2014ANZGOG 0903","volume":"154","author":"Mileshkin","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_66","first-page":"650","article-title":"The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers\u2014A study of the National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Ma","year":"2004","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Lindemann, K., Malander, S., Christensen, R.D., Mirza, M.R., Kristensen, G.B., Aavall-Lundqvist, E., Vergote, I., Rosenberg, P., Boman, K., and Nordstr\u00f8m, B. (2014). Examestane in advanced or recurrent endometrial carcinoma: A prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO). BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-68"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ygyno.2013.02.039","article-title":"Phase II study of fulvestrant 250mg\/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie","volume":"129","author":"Emons","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ygyno.2024.10.006","article-title":"Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent\/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a\/1b EMBER study","volume":"191","author":"Yonemori","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/00000421-200102000-00007","article-title":"Megestrol and Tamoxifen in Patients with Advanced Endometrial Cancer An Eastern Cooperative Oncology Group Study (E4882)","volume":"24","author":"Pandya","year":"2001","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ygyno.2003.09.018","article-title":"Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study","volume":"92","author":"Whitney","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.12.031","article-title":"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study","volume":"164","author":"Slomovitz","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaoncol.2022.1047","article-title":"Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined with Anastrozole in Patients with Hormone Receptor\u2212Positive Recurrent or Metastatic Endometrial Cancer","volume":"8","author":"Heudel","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e000926","DOI":"10.1136\/esmoopen-2020-000926","article-title":"Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers","volume":"5","author":"Zanfagnin","year":"2020","journal-title":"ESMO Open"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor\u2013Positive Recurrent Endometrial Cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1158\/1078-0432.CCR-24-1999","article-title":"A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor\u2013Positive Advanced or Recurrent Endometrial Cancer","volume":"31","author":"Green","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ygyno.2024.12.003","article-title":"Palbociclib plus letrozole in estrogen receptor-positive advanced\/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3\/PALEO trial","volume":"192","author":"Mirza","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41467-025-67087-8","article-title":"Letrozole, abemaciclib and metformin in endometrial cancer: A non-randomized phase 2 trial","volume":"17","author":"Konstantinopoulos","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ygyno.2010.10.015","article-title":"Phase II study of fulvestrant in recurrent\/metastatic endometrial carcinoma: A Gynecologic Oncology Group Study","volume":"120","author":"Covens","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_80","first-page":"1140","article-title":"Female sex steroid-receptors in post-menopausal endometrial carcinoma and biochemical response to an anti-estrogen","volume":"41","author":"Mortel","year":"1981","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2003.11.008","article-title":"Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study","volume":"92","author":"Fiorica","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2007.03.042","article-title":"Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group Study","volume":"106","author":"Singh","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2003.11.014","article-title":"What is the clinical value of adding tamoxifen to progestins in the treament of advanced or recurrent endometrial cancer?","volume":"92","author":"Herzog","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.bpobgyn.2007.08.003","article-title":"Hormonal therapies and gynaecological cancers","volume":"22","author":"Garrett","year":"2008","journal-title":"Best Pr. Res. Clin. Obstet. Gynaecol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/gyno.2000.5865","article-title":"A Phase II Trial of Anastrozole in Advanced Recurrent or Persistent Endometrial Carcinoma: A Gynecologic Oncology Group Study","volume":"78","author":"Rose","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor\u2013Positive Advanced Breast Cancer","volume":"28","author":"Jerusalem","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/ijgc-2023-005229","article-title":"An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent\/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)","volume":"34","author":"Trozzi","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1158\/1078-0432.CCR-24-3905","article-title":"Precision Endocrine Therapy in Endometrial Cancer: Has Its Time Finally Come?","volume":"31","author":"Garg","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e2400882","DOI":"10.1200\/PO-24-00882","article-title":"Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole\/Abemaciclib in Endometrial Cancer","volume":"9","author":"Konstantinopoulos","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"102816","DOI":"10.1016\/j.ijgc.2025.102816","article-title":"Incidence of ESR1 gene mutations among patients with endometrioid endometrial cancer","volume":"36","author":"Jang","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1200\/JCO.2024.42.16_suppl.5598","article-title":"Characterization of ESR1 mutations in endometrial and ovarian cancers","volume":"42","author":"Gaillard","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2019.04.010","article-title":"Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies","volume":"154","author":"Gaillard","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"105755","DOI":"10.1016\/j.esmoop.2025.105755","article-title":"Gene actionability according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) in No Specific Molecular Profile (NSMP) endometrial cancer","volume":"10","author":"Mastrantoni","year":"2025","journal-title":"ESMO Open"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1073\/pnas.0806514106","article-title":"Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation","volume":"106","author":"Salvesen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR Pathway as a Therapeutic Target in Endometrial Cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2014.01.015","article-title":"Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study","volume":"132","author":"Fleming","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/2159-8290.CD-11-0192","article-title":"ER and PI3K Independently Modulate Endocrine Resistance in ER-Positive Breast Cancer","volume":"1","author":"Crowder","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"C19","DOI":"10.1530\/ERC-11-0112","article-title":"Killing the second messenger: Targeting loss of cell cycle control in endocrine-resistant breast cancer","volume":"18","author":"Lange","year":"2011","journal-title":"Endocrine-Related Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/2767-9764.CRC-24-0028","article-title":"Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma","volume":"5","author":"Yang","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ccell.2024.09.009","article-title":"Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion","volume":"42","author":"Kudo","year":"2024","journal-title":"Cancer Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ygyno.2016.10.011","article-title":"Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study","volume":"143","author":"Soliman","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/cam4.353","article-title":"Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer","volume":"4","author":"Schuler","year":"2014","journal-title":"Cancer Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"101348","DOI":"10.1016\/j.gore.2024.101348","article-title":"Combined aromatase, CDK4\/6 and PI3K blockade using letrozole\/abemaciclib\/LY3023414 in endometrial cancer","volume":"52","author":"Konstantinopoulos","year":"2024","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-20-4618","article-title":"A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response","volume":"27","author":"Duska","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: A clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"npj Breast Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"New Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative Advanced Breast Cancer: Results from the Randomized Phase III EMERALD Trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"S1561","DOI":"10.1016\/j.annonc.2025.09.026","article-title":"LBA16 Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, HER2\u2013 aBC) previously treated with a CDK4\/6 inhibitor (i): Primary results of the phase III evERA BC trial","volume":"36","author":"Mayer","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"New Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2505725","article-title":"Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer","volume":"393","author":"Campone","year":"2025","journal-title":"New Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1158\/0008-5472.CAN-24-2608","article-title":"Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer","volume":"85","author":"Bhagwat","year":"2024","journal-title":"Cancer Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40265-025-02266-x","article-title":"Imlunestrant: First Approval","volume":"86","author":"Keam","year":"2025","journal-title":"Drugs"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"RAINBO Research Consortium (2022). Refining adjuvant treatment in endometrial cancer based on molecular features: The RAINBO clinical trial program. Int. J. Gynecol. Cancer, 33, 109\u2013117.","DOI":"10.1136\/ijgc-2022-004039"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41523-022-00482-2","article-title":"Abemaciclib in combination with pembrolizumab for HR+, HER2\u2212 metastatic breast cancer: Phase 1b study","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e007126","DOI":"10.1136\/jitc-2023-007126","article-title":"Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: A phase II study (WJOG11418B NEWFLAME trial)","volume":"11","author":"Masuda","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.humpath.2020.12.003","article-title":"The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: A European Network for Individualized Treatment of Endometrial Cancer collaboration study","volume":"109","author":"Reijnen","year":"2021","journal-title":"Hum. Pathol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1507\/endocrj.KR-114","article-title":"Biological Roles of Estrogen and Progesterone in Human Endometrial Carcinoma\u2014New developments in potential endocrine therapy for endometrial cancer","volume":"54","author":"Ito","year":"2007","journal-title":"Endocr. J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1002\/cncr.34328","article-title":"Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscape","volume":"128","author":"Jamieson","year":"2022","journal-title":"Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ygyno.2024.08.016","article-title":"Excellent concordance of the molecular classification between preoperative biopsy and final hysterectomy in endometrial carcinoma","volume":"190","author":"Kato","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Bartosch, C., Monteiro-Reis, S., Vieira, R., Pereira, A., Rodrigues, M., Jer\u00f3nimo, C., and Lopes, J.M. (2015). Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134969"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/aogs.13586","article-title":"Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis","volume":"98","author":"Raffone","year":"2019","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.23.00470","article-title":"Redefining the Position of Hormonal Therapy in Endometrial Cancer in the Era of Molecular Classification","volume":"42","author":"Pijnenborg","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAI.0000000000000402","article-title":"Immunohistochemical Profiles of Endometrioid Endometrial Carcinomas with and without Metastatic Disease","volume":"26","author":"Geels","year":"2018","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Luijten, M.M.W., van Weelden, W.J., Lalisang, R.I., Bulten, J., Lindemann, K., van Beekhuizen, H.J., Trum, H., Boll, D., Werner, H.M.J., and van Lonkhuijzen, L.R.C.W. (2024). Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma. Cancers, 16.","DOI":"10.3390\/cancers16112084"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/124\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:59:37Z","timestamp":1771509577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":126,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020124"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020124","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]}}}